Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "We expect PDS will fund its operations through licensing revenue."

"To me this is a very positive sign regarding future licensing activity because at an other place the 10Q says the MMP is the only cash resource, hence, not to fund PDS' operations sounds like they are expecting incoming revenues SOON."

I read it differently. My take is PTSC isn't funding PDS, if PTSC isn't recieving any revenue from PDS. When revenues start turning, the PDS funding will recommence. PTSC has already committed to direct financial payments to TPL for litigatigation expenses 60 days past the Markman hearing. But you've already read that, I'm sure.

That's it. That's how I see it.

A big ol' vote of no trust aimed towards Lekrone.

Share
New Message
Please login to post a reply